J&J's canagliflozin may raise heart risks

01/9/2013 | USA Today · Bloomberg

An FDA panel on Tuesday concluded that Johnson & Johnson's experimental diabetes drug canagliflozin may slightly raise the odds of heart attack, stroke or death as it increased bad cholesterol levels in patients compared with two other diabetes medications. The drug, part of a class known as SGLT2 inhibitors, might help control blood glucose levels in patients with type 2 diabetes, as well as aid in weight loss and lowering blood pressure, a company spokesman said.

View Full Article in:

USA Today · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC